Of note, our study was not designed to tease apart the individual contributions of anti-PD-1 and anti-CTLA-4 on Tregs, since anti-CTLA-4 is rarely used for the treatment of breast cancer patients without the addition of anti-PD-1. Here, CTLA4 is linked to breast carcinoma.